

Radiotheranostic agent *development within reach*

Radiomolecular *Precision Oncology*

RPO Group is a radiotheranostic CRO located in the heart of Western Europe, the global epicentre of radiomolecular precision oncology. This collaborative alliance of experts including Prof Dr Richard P Baum and Dr Hugo M L Jansen unites their respective specialities into a flexible, tailor-made approach.

Services

- Clinical Study Management
- Radiomolecular Image Handling & Analysis
- Scientific & Medical Consultancy Services
- Medical Writing
- Molecule Mapping
- Hospital & Site Network
- Safety & Advisory Board
- Legal Representation for non-EU Companies


Location



The Rise of Radiotheranostics *in Clinical Management*

The current radiotheranostic revolution - primed for a rapid expansion in the coming years - is profoundly changing the multidisciplinary care of (metastatic) cancer patients, and may soon be among the most important pillars in clinical management. For Good.

At RPO Group, we enhance the development of radiotheranostics, focusing on surpassing traditional treatments in efficacy and safety. With a high failure rate of over 95% in clinical trials due to safety and efficacy issues, our use of advanced imaging technologies like SPECT-CT, PET-CT, and PET-MRI is key. We precisely identify suitable cancer patients for targeted therapies, leveraging radiotheranostics' unique ability to switch between diagnostic and therapeutic modes within the same molecular structure. This strategy aims to increase the effectiveness of clinical trials and lead the way to safer, more focused cancer treatments.




Get in touch

Do you have questions or requests? Is there anything you'd like to share?
Or would you like to work with us? Don't hesitate to get in touch.

info@rpo-group.com

+32 479 83 87 10

www.rpo-group.com



Molecule mapping.

We focus on the 360°
profiling of theranostic
compounds.



Assessment. We take a
critical look at the safety
and efficacy of the
therapeutic process.



Analysis. We interpret
PET-CT and PET-MRI
scans of patients using
innovative radiolabeled
molecules.



Research. We offer the
operational capacity for
clinical research in
Europe, APAC, and
the USA.



Collaboration.
We work with leading
clinical experts in the field
of (radio)theranostic
medicine.



Clinical study advice. We
design clinical studies for
theranostic treatment.